Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Azacitidine
Drug ID BADD_D00194
Description A pyrimidine nucleoside analogue that inhibits DNA methyltransferase, impairing DNA methylation. It is also an antimetabolite of cytidine, incorporated primarily into RNA. Azacytidine has been used as an antineoplastic agent.
Indications and Usage For treatment of patients with the following French-American-British myelodysplastic syndrome subtypes: refractory anemia or refractory anemia with ringed sideroblasts (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts, refractory anemia with excess blasts in transformation (now classified as acute myelogenous leukemia with multilineage dysplasia), and chronic myelomonocytic leukemia.
Marketing Status Prescription
ATC Code L01BC07
DrugBank ID DB00928
KEGG ID D03021
MeSH ID D001374
PubChem ID 9444
TTD Drug ID D09FAZ
NDC Product Code 43598-678; 59572-740; 16729-306; 71288-115; 16714-927; 0781-3253; 43598-305; 71288-153; 63592-1800; 68001-313; 63759-0015; 67457-254; 59572-730; 70121-1237; 68001-527; 72606-558; 69097-805; 69097-368; 0781-9253; 59572-102; 64679-096; 68554-0104; 66529-0013; 63660-0010; 14096-121; 51991-797; 42385-719; 63323-771; 51916-350; 68001-504; 65129-1222; 72485-201; 43598-465; 53183-4011; 0143-9606; 43817-906; 54893-0029
Synonyms Azacitidine | 5-Azacytidine | 5 Azacytidine | Azacytidine | Vidaza | NSC-102816 | NSC 102816 | NSC102816
Chemical Information
Molecular Formula C8H12N4O5
CAS Registry Number 320-67-2
SMILES C1=NC(=NC(=O)N1C2C(C(C(O2)CO)O)O)N
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Delirium19.13.02.001--
Dementia17.03.01.001; 19.20.02.0010.001598%Not Available
Depressed level of consciousness17.02.04.002--
Depression19.15.01.001--
Dermatitis23.03.04.002--Not Available
Dermatitis allergic23.03.04.003; 10.01.03.0140.001066%Not Available
Dermatitis exfoliative23.03.07.001; 10.01.01.0040.000533%
Diabetes insipidus14.05.07.003; 05.03.03.0040.000533%Not Available
Diabetes mellitus14.06.01.001; 05.06.01.0010.004795%Not Available
Diabetes mellitus inadequate control14.06.01.004; 05.06.01.0040.000533%Not Available
Diarrhoea07.02.01.001--
Diffuse large B-cell lymphoma16.28.02.001; 01.15.02.0010.000208%Not Available
Discomfort08.01.08.003--Not Available
Disorientation19.13.01.002; 17.02.05.015--Not Available
Disseminated intravascular coagulation24.01.01.010; 01.01.02.0020.001042%
Disseminated tuberculosis11.04.01.0010.000799%Not Available
Diverticulitis07.10.02.001; 11.01.07.0030.001865%Not Available
Dizziness17.02.05.003; 24.06.02.007; 02.01.02.004--
Drug eruption23.03.05.001; 10.01.01.005; 08.01.06.015--Not Available
Dry skin23.03.03.001--
Dysgeusia17.02.07.003; 07.14.03.001--
Dyspepsia07.01.02.001--
Dysphagia07.01.06.003--
Dyspnoea22.02.01.004; 02.01.03.002--
Dyspnoea exertional22.02.01.005; 02.01.03.003--Not Available
Dysuria20.02.02.002--
Ear infection11.01.05.001; 04.03.01.006--Not Available
Ecchymosis24.07.06.002; 23.06.01.001; 01.01.03.0010.000799%Not Available
Electrocardiogram QT prolonged13.14.05.004--
Electrolyte imbalance14.05.01.0020.000799%Not Available
The 5th Page    First    Pre   5 6 7 8 9    Next   Last    Total 24 Pages